Literature DB >> 15448750

Alterations of microvascular density in bone metastases of adenocarcinomas.

Tamás Lôrincz1, József Tímár, Miklós Szendrôi.   

Abstract

Bone may provide an extremely fertile microenvironment for angiogenesis. Experimental investigations indicate angiogenesis as a major regulator of bone metastasis development. Vascularization and angiogenic potential is known for most of the primary tumor types, but no studies investigated angiogenesis in bone metastases of human cancers. We have evaluated microvessel density of bone metastases of various cancer types (all adenocarcinomas) and compared to their primary tumors in paraffin samples of 39 patients. Microvessel density was determined by using the hot spot method and the blood vessel marker, CD34. The most vascularized adenocarcinoma was found to be renal cell cancer followed by lung adenocarcinoma, while breast cancer was heterogenous in this respect. Two patterns of modulation of the angiogenic phenotype in the bone metastases emerged in this study, which seemed to be cancer type specific: decreased angiogenic potential characterizing 45% of renal cell cancers and breast cancers of high vascularity in their primary, and increased angiogenic potential characterizing 40% of lung adenocarcinomas and breast cancers of low vascularity in their primary lesion. Our data demonstrate that i., the vascularization of bone metastases is frequently altered compared to the primary tumors, ii., patterns are different in the case of various cancer types. The tumor-type specific alterations of the angiogenic phenotype of cancers, metastatic to the bone, can have a clinical significance when angiosuppressive therapies are considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448750     DOI: 10.1007/bf03033743

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  12 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone.

Authors:  T Yoneda
Journal:  Eur J Cancer       Date:  1998-02       Impact factor: 9.162

3.  Working experience with a new vacuum-accelerated microwave histoprocessor.

Authors:  L Kovács; B Szende; G Elek; K Lapis; O Horváth; I Hiszek; A Tamási; O Schmidt
Journal:  J Pathol       Date:  1996-09       Impact factor: 7.996

Review 4.  Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

Authors:  A Saaristo; T Karpanen; K Alitalo
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

Review 5.  General mechanisms of metastasis.

Authors:  E C Woodhouse; R F Chuaqui; L A Liotta
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

6.  Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis.

Authors:  B Winding; H Misander; C Sveigaard; B Therkildsen; M Jakobsen; T Overgaard; M J Oursler; N T Foged
Journal:  J Cancer Res Clin Oncol       Date:  2000-11       Impact factor: 4.553

Review 7.  Overview of angiogenesis: Biologic implications for antiangiogenic therapy.

Authors:  L M Ellis; W Liu; S A Ahmad; F Fan; Y D Jung; R M Shaheen; N Reinmuth
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

8.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 10.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more
  8 in total

1.  Characterization of a new renal cell carcinoma bone metastasis mouse model.

Authors:  Anne Strube; Elizaveta Stepina; Dominik Mumberg; Arne Scholz; Peter Hauff; Sanna-Maria Käkönen
Journal:  Clin Exp Metastasis       Date:  2010-05-05       Impact factor: 5.150

2.  Steal phenomenon in the lower limb: presentation of a case with osseous metastases secondary to renal cell carcinoma and review of the literature.

Authors:  Mohammed Asha; Husam Ibrahim; Abdalla Khidir Eisawi; Richard Orme; Andrew Houghton
Journal:  BMJ Case Rep       Date:  2009-03-24

3.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Authors:  Junhua Mai; Yi Huang; Chaofeng Mu; Guodong Zhang; Rong Xu; Xiaojing Guo; Xiaojun Xia; David E Volk; Ganesh L Lokesh; Varatharasa Thiviyanathan; David G Gorenstein; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

Review 4.  Genomics of renal cell cancer-- does it provide breakthrough?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

5.  Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Authors:  Attila Szendrői; A Marcell Szász; Magdolna Kardos; Anna-Mária Tőkés; Roni Idan; Miklós Szűcs; Janina Kulka; Péter Nyirády; Miklós Szendrői; Zoltán Szállási; Balázs Győrffy; József Tímár
Journal:  Oncotarget       Date:  2016-07-05

6.  Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma.

Authors:  Longsheng Wang; Shaojun Chen; Junfeng Zhang; Shiyu Mao; Weipu Mao; Wentao Zhang; Yadong Guo; Yuan Wu; Ruiliang Wang; Yang Yan; Xudong Yao
Journal:  Cancer Manag Res       Date:  2019-03-19       Impact factor: 3.989

7.  Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.

Authors:  Aude I Segaliny; Jason L Cheng; Henry P Farhoodi; Michael Toledano; Chih Chun Yu; Beatrice Tierra; Leanne Hildebrand; Linan Liu; Michael J Liao; Jaedu Cho; Dongxu Liu; Lizhi Sun; Gultekin Gulsen; Min-Ying Su; Robert L Sah; Weian Zhao
Journal:  EBioMedicine       Date:  2019-07-04       Impact factor: 8.143

Review 8.  Hypoxia Signaling in Cancer: From Basics to Clinical Practice.

Authors:  Anna Sebestyén; László Kopper; Titanilla Dankó; József Tímár
Journal:  Pathol Oncol Res       Date:  2021-05-03       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.